查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193118

抗球蟲藥市場：按藥物類別（離子載體、合成藥物）、藥物作用（靜態球蟲、殺球蟲）、動物類型（家禽、牛等）：全球機會分析和行業預測，2021-2031 年

Anticoccidial Drugs Market By Drug Class (Ionophore, Synthetic Drugs), By Drug Action (Coccidiostatic, Coccidiocidal), By Animal Type (Poultry, Cattle, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 220 Pages | 商品交期: 2-3個工作天內

價格

2021 年全球抗球蟲藥市場價值 1.713 億美元，預計 2022 年至 2031 年復合年增長率為 4.2%，2031 年達到 2.578 億美元。

球蟲病是家禽中最常見的疾病之一，由艾美球蟲屬的原生動物寄生蟲引起。 這些寄生蟲是強制性細胞內寄生蟲，具有復雜的生命週期，包括有性和無性階段。 這些寄生蟲生活在腸道中，易患其他疾病（壞死性腸炎），並降低該器官吸收營養的能力。 該病通過昆蟲和野鳥等機械媒介傳播。 然而，在野生鳥類中，卵（卵囊）是機械運輸的，但這些寄生蟲是宿主特異性的，因此野生鳥類不能作為生物宿主。 因此，可以藉助抗球蟲藥物來控制疾病。 由於肉雞的生命週期較短，可採用球蟲等殺蟲劑徹底消滅腸道內的艾美球蟲。

抗球蟲藥物市場的增長是由先進抗球蟲藥物的不斷發展推動的，政府加大力度提高對球蟲病及其治療的認識。 此外，對肉類和牛奶等動物蛋白食品的高需求、抗球蟲藥物合同開發的增加以及製藥和生物技術行業的發展也在推動市場增長。 然而，嚴格的政府法規限制在牲畜中使用抗球蟲藥物以及疫苗和草藥等替代藥物的使用預計會阻礙該市場的增長。 相反，提高對價格可承受的新產品的認識有望在市場上創造有利可圖的機會。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • 分析 COVID-19 對市場的影響

第 4 章抗球蟲藥市場：按治療類別分類

  • 概覽
    • 市場規模和預測
  • 離子載體
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 合成藥物
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章抗球蟲藥物市場：按效力

  • 概覽
    • 市場規模和預測
  • 殺菌劑
    • 主要市場趨勢、增長因素和機遇
    • 各地區的市場規模和預測
    • 市場份額分析：按國家/地區分類
  • 殺菌劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章抗球蟲藥市場：按動物類型分類

  • 概覽
    • 市場規模和預測
  • 家禽
    • 主要市場趨勢、增長因素和機遇
    • 各地區的市場規模和預測
    • 市場份額分析：按國家/地區分類
  • 牛肉
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章抗球蟲藥市場：按地區分類

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按藥物類別
    • 北美市場規模和預測：按毒品行動
    • 北美市場規模和預測：按動物類型
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按藥物類別
    • 歐洲市場規模和預測：按毒品行動
    • 歐洲市場規模和預測：按動物類型
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機會
    • 按藥物類別劃分的亞太市場規模和預測
    • 亞太市場規模和預測：按藥物作用
    • 亞太地區市場規模和按動物類型預測
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按藥物類別
    • LAMEA 市場規模和預測：按藥物作用
    • LAMEA 市場規模和預測：按動物類型
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉美地區

第八章公司情況

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 定位頂級公司，2021 年
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第九章公司簡介

  • boehringer ingelheim animal health-us
  • Ceva sante animale
  • Huvepharma EOOD
  • Merck & Co., Inc
  • Venkateshwara hatcheries Private Limited
  • Dosh Pharmaceuticals
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc
  • Bayer AG
Product Code: A14844

The global anticoccidial drugs market was valued at $171.3 million in 2021, and is projected to reach $257.8 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.

Coccidiosis is one of the most common diseases in the poultry population is caused by protozoan parasites of the genus Eimeria. These are obligated intracellular parasites with complex life cycles including sexual and asexual stages. These parasites affect the intestine making it prone to other diseases (necrotic enteritis) and reducing the ability of this organ to absorb nutrients. This disease is transmitted or spread by mechanical carriers such as insects and wild birds. However, the Eimeria eggs (oocysts) can be mechanically transported by wild birds, these parasites are host-specific and thus wild birds do not serve as a biological reservoir. Hence, this disease can be controlled by the help of anticoccidial drugs. The short life cycle of a broiler eliminates Eimeria completely from the gut by using the drugs like coccidicides that kill the parasites.

The growth of the anticoccidial drugs market is driven by the increase in development of advanced anticoccidial drugs, increase in the government initiatives for the awareness about the coccidiosis and its medications. Moreover, the high demand of animal protein food such as meat, milk, and others, increase in the outsourcing of the development of the anticoccidial drugs, and the development in the pharmaceutical and biotechnology industries also helps in the growth of the market. However, a stringent government regulations that restricts the usage of anticoccidial drugs in livestock and the use of alternative medicines such as vaccines and herbal medicines to treat coccidiosis are expected to hinder the growth of this market. Conversely, the rise in awareness about the new products available at affordable rates is expected to create lucrative opportunities for the market.

The global anticoccidial drugs market is segmented based on drug class, drug action, animal type, and region. On the basis of drug class, the market is bifurcated into ionophore and synthetic drugs. On the basis of drug action, the market is classified into coccidiostatic and coccidiocidal. On the basis of animal type, the market is classified into poultry, cattle and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key market players operating in this market include Bayer AG, Boehringer Ingelheim International GmbH, Ceva sante animale, Dosh Pharmaceuticals Private Limited, Huvepharma EOOD, Merck & Co., Inc., Venkateshwara hatcheries Private Limited, Vetoquinol SA, Virbac SA, Zoetis Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anticoccidial drugs market analysis from 2021 to 2031 to identify the prevailing anticoccidial drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the anticoccidial drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global anticoccidial drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Ionophore
  • Synthetic Drugs

By Drug Action

  • Coccidiostatic
  • Coccidiocidal

By Animal Type

  • Poultry
  • Cattle
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • boehringer ingelheim animal health - us
    • Ceva sante animale
    • Huvepharma EOOD
    • Merck & Co., Inc
    • Venkateshwara hatcheries Private Limited
    • Dosh Pharmaceuticals
    • Vetoquinol SA
    • Virbac SA
    • Zoetis Inc
    • Bayer AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
    • 3.4.2.Restraints
    • 3.4.3.Opportunities
  • 3.5.COVID-19 Impact Analysis on the market

CHAPTER 4: ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Ionophore
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Synthetic Drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Coccidiostatic
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Coccidiocidal
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Poultry
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Cattle
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: ANTICOCCIDIAL DRUGS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Class
    • 7.2.3 North America Market size and forecast, by Drug Action
    • 7.2.4 North America Market size and forecast, by Animal Type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Drug Class
      • 7.2.5.1.3 Market size and forecast, by Drug Action
      • 7.2.5.1.4 Market size and forecast, by Animal Type
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Drug Class
      • 7.2.5.2.3 Market size and forecast, by Drug Action
      • 7.2.5.2.4 Market size and forecast, by Animal Type
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Drug Class
      • 7.2.5.3.3 Market size and forecast, by Drug Action
      • 7.2.5.3.4 Market size and forecast, by Animal Type
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Class
    • 7.3.3 Europe Market size and forecast, by Drug Action
    • 7.3.4 Europe Market size and forecast, by Animal Type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Drug Class
      • 7.3.5.1.3 Market size and forecast, by Drug Action
      • 7.3.5.1.4 Market size and forecast, by Animal Type
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Drug Class
      • 7.3.5.2.3 Market size and forecast, by Drug Action
      • 7.3.5.2.4 Market size and forecast, by Animal Type
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Drug Class
      • 7.3.5.3.3 Market size and forecast, by Drug Action
      • 7.3.5.3.4 Market size and forecast, by Animal Type
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Drug Class
      • 7.3.5.4.3 Market size and forecast, by Drug Action
      • 7.3.5.4.4 Market size and forecast, by Animal Type
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Drug Class
      • 7.3.5.5.3 Market size and forecast, by Drug Action
      • 7.3.5.5.4 Market size and forecast, by Animal Type
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Drug Class
      • 7.3.5.6.3 Market size and forecast, by Drug Action
      • 7.3.5.6.4 Market size and forecast, by Animal Type
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug Action
    • 7.4.4 Asia-Pacific Market size and forecast, by Animal Type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Drug Class
      • 7.4.5.1.3 Market size and forecast, by Drug Action
      • 7.4.5.1.4 Market size and forecast, by Animal Type
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Drug Class
      • 7.4.5.2.3 Market size and forecast, by Drug Action
      • 7.4.5.2.4 Market size and forecast, by Animal Type
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Drug Class
      • 7.4.5.3.3 Market size and forecast, by Drug Action
      • 7.4.5.3.4 Market size and forecast, by Animal Type
      • 7.4.5.4 India
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Drug Class
      • 7.4.5.4.3 Market size and forecast, by Drug Action
      • 7.4.5.4.4 Market size and forecast, by Animal Type
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Drug Class
      • 7.4.5.5.3 Market size and forecast, by Drug Action
      • 7.4.5.5.4 Market size and forecast, by Animal Type
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Drug Class
      • 7.4.5.6.3 Market size and forecast, by Drug Action
      • 7.4.5.6.4 Market size and forecast, by Animal Type
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Class
    • 7.5.3 LAMEA Market size and forecast, by Drug Action
    • 7.5.4 LAMEA Market size and forecast, by Animal Type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Drug Class
      • 7.5.5.1.3 Market size and forecast, by Drug Action
      • 7.5.5.1.4 Market size and forecast, by Animal Type
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Drug Class
      • 7.5.5.2.3 Market size and forecast, by Drug Action
      • 7.5.5.2.4 Market size and forecast, by Animal Type
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Drug Class
      • 7.5.5.3.3 Market size and forecast, by Drug Action
      • 7.5.5.3.4 Market size and forecast, by Animal Type
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Drug Class
      • 7.5.5.4.3 Market size and forecast, by Drug Action
      • 7.5.5.4.4 Market size and forecast, by Animal Type

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Top player positioning, 2021
  • 8.5. Competitive Dashboard
  • 8.6. Competitive Heatmap
  • 8.7. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 boehringer ingelheim animal health - us
    • 9.1.1 Company overview
    • 9.1.2 Key Executives
    • 9.1.3 Company snapshot
    • 9.1.4 Operating business segments
    • 9.1.5 Product portfolio
    • 9.1.6 Business performance
    • 9.1.7 Key strategic moves and developments
  • 9.2 Ceva sante animale
    • 9.2.1 Company overview
    • 9.2.2 Key Executives
    • 9.2.3 Company snapshot
    • 9.2.4 Operating business segments
    • 9.2.5 Product portfolio
    • 9.2.6 Business performance
    • 9.2.7 Key strategic moves and developments
  • 9.3 Huvepharma EOOD
    • 9.3.1 Company overview
    • 9.3.2 Key Executives
    • 9.3.3 Company snapshot
    • 9.3.4 Operating business segments
    • 9.3.5 Product portfolio
    • 9.3.6 Business performance
    • 9.3.7 Key strategic moves and developments
  • 9.4 Merck & Co., Inc
    • 9.4.1 Company overview
    • 9.4.2 Key Executives
    • 9.4.3 Company snapshot
    • 9.4.4 Operating business segments
    • 9.4.5 Product portfolio
    • 9.4.6 Business performance
    • 9.4.7 Key strategic moves and developments
  • 9.5 Venkateshwara hatcheries Private Limited
    • 9.5.1 Company overview
    • 9.5.2 Key Executives
    • 9.5.3 Company snapshot
    • 9.5.4 Operating business segments
    • 9.5.5 Product portfolio
    • 9.5.6 Business performance
    • 9.5.7 Key strategic moves and developments
  • 9.6 Dosh Pharmaceuticals
    • 9.6.1 Company overview
    • 9.6.2 Key Executives
    • 9.6.3 Company snapshot
    • 9.6.4 Operating business segments
    • 9.6.5 Product portfolio
    • 9.6.6 Business performance
    • 9.6.7 Key strategic moves and developments
  • 9.7 Vetoquinol SA
    • 9.7.1 Company overview
    • 9.7.2 Key Executives
    • 9.7.3 Company snapshot
    • 9.7.4 Operating business segments
    • 9.7.5 Product portfolio
    • 9.7.6 Business performance
    • 9.7.7 Key strategic moves and developments
  • 9.8 Virbac SA
    • 9.8.1 Company overview
    • 9.8.2 Key Executives
    • 9.8.3 Company snapshot
    • 9.8.4 Operating business segments
    • 9.8.5 Product portfolio
    • 9.8.6 Business performance
    • 9.8.7 Key strategic moves and developments
  • 9.9 Zoetis Inc
    • 9.9.1 Company overview
    • 9.9.2 Key Executives
    • 9.9.3 Company snapshot
    • 9.9.4 Operating business segments
    • 9.9.5 Product portfolio
    • 9.9.6 Business performance
    • 9.9.7 Key strategic moves and developments
  • 9.10 Bayer AG
    • 9.10.1 Company overview
    • 9.10.2 Key Executives
    • 9.10.3 Company snapshot
    • 9.10.4 Operating business segments
    • 9.10.5 Product portfolio
    • 9.10.6 Business performance
    • 9.10.7 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. ANTICOCCIDIAL DRUGS MARKET FOR IONOPHORE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. ANTICOCCIDIAL DRUGS MARKET FOR SYNTHETIC DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. ANTICOCCIDIAL DRUGS MARKET FOR COCCIDIOSTATIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. ANTICOCCIDIAL DRUGS MARKET FOR COCCIDIOCIDAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. ANTICOCCIDIAL DRUGS MARKET FOR POULTRY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. ANTICOCCIDIAL DRUGS MARKET FOR CATTLE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. ANTICOCCIDIAL DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. ANTICOCCIDIAL DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. U.S. ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. U.S. ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. CANADA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. CANADA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. UK ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. UK ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. ITALY ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. ITALY ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. CHINA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. CHINA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: KEY EXECUTIVES
  • TABLE 86.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: COMPANY SNAPSHOT
  • TABLE 87.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: OPERATING SEGMENTS
  • TABLE 88.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: PRODUCT PORTFOLIO
  • TABLE 89.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: NET SALES
  • TABLE 90.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: KEY STRATERGIES
  • TABLE 92.CEVA SANTE ANIMALE: KEY EXECUTIVES
  • TABLE 92.CEVA SANTE ANIMALE: COMPANY SNAPSHOT
  • TABLE 93.CEVA SANTE ANIMALE: OPERATING SEGMENTS
  • TABLE 94.CEVA SANTE ANIMALE: PRODUCT PORTFOLIO
  • TABLE 95.CEVA SANTE ANIMALE: NET SALES
  • TABLE 96.CEVA SANTE ANIMALE: KEY STRATERGIES
  • TABLE 98.HUVEPHARMA EOOD: KEY EXECUTIVES
  • TABLE 98.HUVEPHARMA EOOD: COMPANY SNAPSHOT
  • TABLE 99.HUVEPHARMA EOOD: OPERATING SEGMENTS
  • TABLE 100.HUVEPHARMA EOOD: PRODUCT PORTFOLIO
  • TABLE 101.HUVEPHARMA EOOD: NET SALES
  • TABLE 102.HUVEPHARMA EOOD: KEY STRATERGIES
  • TABLE 104.MERCK & CO., INC: KEY EXECUTIVES
  • TABLE 104.MERCK & CO., INC: COMPANY SNAPSHOT
  • TABLE 105.MERCK & CO., INC: OPERATING SEGMENTS
  • TABLE 106.MERCK & CO., INC: PRODUCT PORTFOLIO
  • TABLE 107.MERCK & CO., INC: NET SALES
  • TABLE 108.MERCK & CO., INC: KEY STRATERGIES
  • TABLE 110.VENKATESHWARA HATCHERIES PRIVATE LIMITED: KEY EXECUTIVES
  • TABLE 110.VENKATESHWARA HATCHERIES PRIVATE LIMITED: COMPANY SNAPSHOT
  • TABLE 111.VENKATESHWARA HATCHERIES PRIVATE LIMITED: OPERATING SEGMENTS
  • TABLE 112.VENKATESHWARA HATCHERIES PRIVATE LIMITED: PRODUCT PORTFOLIO
  • TABLE 113.VENKATESHWARA HATCHERIES PRIVATE LIMITED: NET SALES
  • TABLE 114.VENKATESHWARA HATCHERIES PRIVATE LIMITED: KEY STRATERGIES
  • TABLE 116.DOSH PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 116.DOSH PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 117.DOSH PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 118.DOSH PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 119.DOSH PHARMACEUTICALS: NET SALES
  • TABLE 120.DOSH PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 122.VETOQUINOL SA: KEY EXECUTIVES
  • TABLE 122.VETOQUINOL SA: COMPANY SNAPSHOT
  • TABLE 123.VETOQUINOL SA: OPERATING SEGMENTS
  • TABLE 124.VETOQUINOL SA: PRODUCT PORTFOLIO
  • TABLE 125.VETOQUINOL SA: NET SALES
  • TABLE 126.VETOQUINOL SA: KEY STRATERGIES
  • TABLE 128.VIRBAC SA: KEY EXECUTIVES
  • TABLE 128.VIRBAC SA: COMPANY SNAPSHOT
  • TABLE 129.VIRBAC SA: OPERATING SEGMENTS
  • TABLE 130.VIRBAC SA: PRODUCT PORTFOLIO
  • TABLE 131.VIRBAC SA: NET SALES
  • TABLE 132.VIRBAC SA: KEY STRATERGIES
  • TABLE 134.ZOETIS INC: KEY EXECUTIVES
  • TABLE 134.ZOETIS INC: COMPANY SNAPSHOT
  • TABLE 135.ZOETIS INC: OPERATING SEGMENTS
  • TABLE 136.ZOETIS INC: PRODUCT PORTFOLIO
  • TABLE 137.ZOETIS INC: NET SALES
  • TABLE 138.ZOETIS INC: KEY STRATERGIES
  • TABLE 140.BAYER AG: KEY EXECUTIVES
  • TABLE 140.BAYER AG: COMPANY SNAPSHOT
  • TABLE 141.BAYER AG: OPERATING SEGMENTS
  • TABLE 142.BAYER AG: PRODUCT PORTFOLIO
  • TABLE 143.BAYER AG: NET SALES
  • TABLE 144.BAYER AG: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1. SEGMENTATION OF ANTICOCCIDIAL DRUGS MARKET,2021-2031
  • FIGURE 2.ANTICOCCIDIAL DRUGS MARKET,2021-2031
  • FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 4.PORTER FIVE-1
  • FIGURE 5.PORTER FIVE-2
  • FIGURE 6.PORTER FIVE-3
  • FIGURE 7.PORTER FIVE-4
  • FIGURE 8.PORTER FIVE-5
  • FIGURE 9.ANTICOCCIDIAL DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10.ANTICOCCIDIAL DRUGS MARKET,BY DRUG CLASS,2021(%)
  • FIGURE 11.COMPARATIVE SHARE ANALYSIS OF IONOPHORE ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF SYNTHETIC DRUGS ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 13.ANTICOCCIDIAL DRUGS MARKET,BY DRUG ACTION,2021(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF COCCIDIOSTATIC ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF COCCIDIOCIDAL ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 16.ANTICOCCIDIAL DRUGS MARKET,BY ANIMAL TYPE,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF POULTRY ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CATTLE ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 20.ANTICOCCIDIAL DRUGS MARKET BY REGION,2021
  • FIGURE 21.U.S. ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 22.CANADA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 23.MEXICO ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 24.GERMANY ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 25.FRANCE ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 26.UK ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 27.ITALY ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 28.SPAIN ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 29.REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 30.JAPAN ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 31.CHINA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 32.AUSTRALIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 33.INDIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 34.SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 36.BRAZIL ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 37.SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 44.TOP PLAYER POSITIONING, 2021
  • FIGURE 45.COMPETITIVE DASHBOARD
  • FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 47.BOEHRINGER INGELHEIM ANIMAL HEALTH - US.: NET SALES ($MILLION)
  • FIGURE 48.CEVA SANTE ANIMALE.: NET SALES ($MILLION)
  • FIGURE 49.HUVEPHARMA EOOD.: NET SALES ($MILLION)
  • FIGURE 50.MERCK & CO., INC.: NET SALES ($MILLION)
  • FIGURE 51.VENKATESHWARA HATCHERIES PRIVATE LIMITED.: NET SALES ($MILLION)
  • FIGURE 52.DOSH PHARMACEUTICALS.: NET SALES ($MILLION)
  • FIGURE 53.VETOQUINOL SA.: NET SALES ($MILLION)
  • FIGURE 54.VIRBAC SA.: NET SALES ($MILLION)
  • FIGURE 55.ZOETIS INC.: NET SALES ($MILLION)
  • FIGURE 56.BAYER AG.: NET SALES ($MILLION)